Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, based in New York, is blazing a trail in rare disease and diabetic complications research in the United States. The company is developing innovative products with a central focus on the central nervous system. Its flagship product candidate, AT-007, has achieved remarkable success in phase III trials, including completion of testing in healthy volunteers and adults for galactosemia treatment. The product is currently undergoing clinical trials in children for the treatment of galactosemia, as well as for sorbitol dehydrogenase deficiency and phosphomannomutase enzyme-CDG. Applied Therapeutics' other promising offerings include AT-001, which is in phase III trials for diabetic cardiomyopathy treatment and diabetic peripheral neuropathy. Additionally, AT-003 is under preclinical study for diabetic retinopathy treatment. With impressive progress since its incorporation in 2016, Applied Therapeutics is a force to be reckoned with in the biopharmaceutical industry.